MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

Search

Bayer AG

Open

BrancheFinanzen

23.075 2.67

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

22.415

Max

23.135

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.9B

-328M

Verkäufe

1.8B

12B

KGV

Branchendurchschnitt

30.9

20.525

EPS

1.05

Dividendenrendite

0.52

Gewinnspanne

-2.796

Angestellte

90,587

EBITDA

615M

1.7B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+18.73% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.52%

4.36%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-599M

21B

Vorheriger Eröffnungskurs

20.41

Vorheriger Schlusskurs

23.075

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Bayer AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. März 2025, 09:37 UTC

Wichtige Markttreiber

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5. März 2025, 11:21 UTC

Ergebnisse

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5. März 2025, 08:45 UTC

Ergebnisse

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5. März 2025, 07:26 UTC

Ergebnisse

Bayer Warns of Lower Earnings as Work Continues on Turnaround

14. Apr. 2025, 13:00 UTC

Top News

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

7. Apr. 2025, 17:01 UTC

Market Talk

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2. Apr. 2025, 09:27 UTC

Heiße Aktien

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10. März 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

5. März 2025, 13:39 UTC

Market Talk
Ergebnisse

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5. März 2025, 13:26 UTC

Market Talk

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5. März 2025, 08:30 UTC

Market Talk
Ergebnisse

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5. März 2025, 06:41 UTC

Ergebnisse

Bayer Launches Plan to Boost Profitability at Crop Science

5. März 2025, 06:40 UTC

Ergebnisse

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5. März 2025, 06:39 UTC

Ergebnisse

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5. März 2025, 06:39 UTC

Ergebnisse

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5. März 2025, 06:36 UTC

Ergebnisse

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5. März 2025, 06:35 UTC

Ergebnisse

Bayer Guidance is on a Currency Adjusted Basis

5. März 2025, 06:34 UTC

Ergebnisse

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5. März 2025, 06:34 UTC

Ergebnisse

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5. März 2025, 06:33 UTC

Ergebnisse

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5. März 2025, 06:33 UTC

Ergebnisse

Bayer Sees 2025 Sales EUR45B-EUR47B

5. März 2025, 06:32 UTC

Ergebnisse

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5. März 2025, 06:31 UTC

Ergebnisse

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5. März 2025, 06:31 UTC

Ergebnisse

Bayer 4Q Net Loss EUR335M

5. März 2025, 06:31 UTC

Ergebnisse

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5. März 2025, 06:31 UTC

Ergebnisse

Bayer 4Q Ebitda Before Special Items EUR2.35B

5. März 2025, 06:31 UTC

Ergebnisse

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5. März 2025, 06:31 UTC

Ergebnisse

Bayer 4Q Sales EUR11.73B

13. Jan. 2025, 21:05 UTC

Top News

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9. Jan. 2025, 15:06 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Didn't Disclose Financial Details

Peer-Vergleich

Kursveränderung

Bayer AG Prognose

Kursziel

By TipRanks

18.73% Vorteil

12-Monats-Prognose

Durchschnitt 26.69 EUR  18.73%

Hoch 33 EUR

Tief 22 EUR

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bayer AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

11 ratings

1

Buy

10

Halten

0

Sell

Technischer Score

By Trading Central

21 / N/AUnterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.